Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies.
Benjamin R OshrineDavid ShyrGregory HaleAleksandra PetrovicPublished in: Pediatric transplantation (2019)
Post-transplant azacitidine in children is safe and feasible, with most patients successfully receiving all planned cycles. Despite the limitations of a small cohort, low relapse incidence suggests a potential benefit in disease control that warrants further investigation.